Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD09 in Persistent HPV16 Infection in the Anal Region
NCT07710664Phase 1Recruiting
- Sponsor
- Newish Biotechnology
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of NWRD09 in human papillomavirus type 16 infection (2 arms), sponsored by Newish Biotechnology. Primary endpoint: Incidence and severity of local and systemic adverse events at 28 weeks. Started Jul 2026; status: recruiting.
02
Drugs
NWRD09
03
Conditions
human papillomavirus type 16 infection
Beyond the preview
Go deeper on NCT07710664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710664.